Type Public Limited Company Industry Pharmaceutical Products Sativex® Founded 1998 CEO Justin Gover (Jan 1999–) | Traded as NASDAQ: GWPHLSE: GWP Key people Justin Gover (CEO) Revenue $33.8 million (2001) Headquarters Salisbury, United Kingdom | |
 | ||
Stock price GWPRF (OTCMKTS) US$ 10.66 -0.15 (-1.36%)8 Mar, 4:00 PM GMT-5 - Disclaimer Founders Brian Whittle, Geoffrey W. Guy Subsidiaries Cannabinoid Research Institute Limited, GW Pharma Limited, GW Research Ltd | ||
Gw pharmaceuticals ceo pot play mad money cnbc
GW Pharmaceuticals is a British biopharmaceutical company known for its multiple sclerosis treatment product Sativex, nabiximols (brand name, Sativex). Sativex is the first natural cannabis plant derivative to gain market approval in any country. Another cannabis-based product, Epidiolex, for treatment of epilepsy, underwent phase 3 clinical trials in 2015.
Contents
Gw pharmaceuticals ceo a big step forward mad money cnbc
Background
Doctors Geoffrey Guy and Brian Whittle founded GW Pharmaceuticals in 1998. That year they obtained a cultivation license from the United Kingdom Home Office and the MHRA, allowing GW Pharmaceuticals to cultivate cannabis from seeds and clones to conduct scientific research concerning the medicinal uses of the plant.
HortaPharm
In July 1998, GW Pharmaceuticals collaborated with HortaPharm B.V., a cannabis research and development business based in the Netherlands, founded by two expert horticulturists from California, Robert Connell Clarke and David Paul Watson, also known as 'Sam the Skunkman'. HortaPharm grew medicinal strains for the Dutch government.
Sativex
Nabiximols (trade name Sativex) is a botanical drug that is a cannabis extract, administered as a mouth spray; it was approved in the UK in 2010 as a treatment for multiple sclerosis (MS) patients to alleviate neuropathic pain, spasticity, overactive bladder, and other symptoms.
Nabiximols is made with two unknown Cannabis strains, and is extracted with ethanol and carbon dioxide.
In 2011, GW Pharmaceuticals concluded a partnership with Bayer for the distribution of Sativex in the UK, and have an estimated annual production of 100 tons of medicinal cannabis since 2012.
Epidiolex
In 2015 GW Pharmaceutical initiated Phase 3 clinical trials of an investigational cannabidiol, Epidiolex, for treatment of two orphan conditions in children – Dravet and Lennox-Gastaut syndromes. GW also received fast track designation from the US FDA for use of the drug candidate to treat newborns with epilepsy.